JP2012524120A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524120A5
JP2012524120A5 JP2012507283A JP2012507283A JP2012524120A5 JP 2012524120 A5 JP2012524120 A5 JP 2012524120A5 JP 2012507283 A JP2012507283 A JP 2012507283A JP 2012507283 A JP2012507283 A JP 2012507283A JP 2012524120 A5 JP2012524120 A5 JP 2012524120A5
Authority
JP
Japan
Prior art keywords
derivative
derivatives
biologically active
peptides
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507283A
Other languages
English (en)
Japanese (ja)
Other versions
JP6101077B2 (ja
JP2012524120A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031559 external-priority patent/WO2010123798A2/en
Publication of JP2012524120A publication Critical patent/JP2012524120A/ja
Publication of JP2012524120A5 publication Critical patent/JP2012524120A5/ja
Application granted granted Critical
Publication of JP6101077B2 publication Critical patent/JP6101077B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507283A 2009-04-20 2010-04-19 生体分子を細胞へトランスフェクトするための組成物 Expired - Fee Related JP6101077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17094509P 2009-04-20 2009-04-20
US61/170,945 2009-04-20
PCT/US2010/031559 WO2010123798A2 (en) 2009-04-20 2010-04-19 Compositions for transfection of biomolecules into cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015171776A Division JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Publications (3)

Publication Number Publication Date
JP2012524120A JP2012524120A (ja) 2012-10-11
JP2012524120A5 true JP2012524120A5 (enExample) 2013-06-06
JP6101077B2 JP6101077B2 (ja) 2017-03-22

Family

ID=43011700

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012507283A Expired - Fee Related JP6101077B2 (ja) 2009-04-20 2010-04-19 生体分子を細胞へトランスフェクトするための組成物
JP2015171776A Expired - Fee Related JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015171776A Expired - Fee Related JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Country Status (7)

Country Link
US (1) US11738084B2 (enExample)
EP (1) EP2421952B1 (enExample)
JP (2) JP6101077B2 (enExample)
KR (1) KR101742332B1 (enExample)
AU (1) AU2010239463B2 (enExample)
HU (1) HUE028642T2 (enExample)
WO (1) WO2010123798A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
JP6208767B2 (ja) * 2012-10-23 2017-10-04 エコール スペリュール デ フィジーク エ シミ アンドゥストリエル デ ラ ヴィル デ パリ 複数回逐次的に形成し、切断することができる可逆的共有結合を含む粒子
CN103849650B (zh) * 2013-10-14 2018-08-03 王深明 功能化纳米姜黄素的基因导入材料及制备方法
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
SG11201805375PA (en) 2016-02-04 2018-07-30 Stem Cell Theranostics Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN108330102B (zh) * 2018-03-14 2020-02-14 江南大学 一株泰妙菌素单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954515A (enExample) 1972-10-03 1974-05-27
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
JP2524406B2 (ja) * 1988-07-05 1996-08-14 田辺製薬株式会社 パイロジェン定量方法
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6194469B1 (en) 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
ES2243229T3 (es) * 1999-02-03 2005-12-01 Powderject Res Ltd Formulaciones de particulas de hidrogel.
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
AU2001273128C1 (en) * 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2263859T3 (es) * 2003-02-18 2006-12-16 Clinique La Prairie Research Sa Composiciones qu4e comprenden hemoglobina fetal y endotoxina bacteriana y opcionalmente componentes de higado fetal adicionales.
US7785769B2 (en) * 2003-07-25 2010-08-31 The United States of America as reprsented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
CA2606349C (en) * 2005-01-28 2019-03-05 Galen Bio, Inc. Immunologically active compositions
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20070281036A1 (en) * 2005-12-19 2007-12-06 University Of Vermont And State Agricultural College System and method of delivering a desired material to a cell
US8288124B2 (en) * 2008-11-20 2012-10-16 Abbott Laboratories Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
ES2397909B1 (es) * 2011-05-05 2014-06-06 Universidad De Zaragoza Procedimiento de obtención de materiales multifuncionalizados

Similar Documents

Publication Publication Date Title
JP2012524120A5 (enExample)
JP2021074025A5 (enExample)
Kiso et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
JP2019068829A5 (enExample)
JP2018529656A5 (enExample)
JP2015516989A5 (enExample)
BRPI0915928B8 (pt) anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos
CL2008001659A1 (es) Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades.
BR112012027030A2 (pt) partículas abrasivas conformadas de cerâmica, métodos de preparo das mesmas e artigos abrasivos contendo as mesmas
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
EA201890367A1 (ru) Композиции и способы для лиофильных форм наночастиц
AU2009282962A8 (en) Compounds as kinase inhibitors
JP2015523072A5 (enExample)
JP2016510747A5 (enExample)
WO2010123798A3 (en) Compositions for transfection of biomolecules into cells
JP2010536929A5 (enExample)
WO2008150276A3 (en) Virus coated nanoparticles and uses thereof
PE20140962A1 (es) Una formulacion farmaceutica solida
Fernandes et al. Glycogen synthase kinase-3 inhibition by CHIR99021 promotes alveolar epithelial cell proliferation and lung regeneration in the lipopolysaccharide-induced acute lung injury mouse model
Mata-Martínez et al. Purinergic signaling in non-parenchymal liver cells
SG10201501376XA (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
Sudi et al. The pleiotropic role of extracellular atp in myocardial remodelling